Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss. Issue 2 (2nd December 2013)

• Record Type: Journal Article
• Authors: Pelletier, Jean-Pierre; Roubille, Camille; Raynauld, Jean-Pierre; Abram, François; Dorais, Marc; Delorme, Philippe; Martel-Pelletier, Johanne
• Is Part Of: Annals of the rheumatic diseases. Volume 74:Issue 2(2015)
• Page Start: 422
• Page End: 429
• Publication Date: 2013-12-02
• Subjects: Knee Osteoarthritis -- Magnetic Resonance Imaging -- Osteoarthritis; Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2013-203989
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Objective: To explore, using MRI, the disease-modifying effect of strontium ranelate (SrRan) treatment on cartilage volume loss (CVL) and bone marrow lesions (BMLs) in a subset of patients from a Phase III clinical trial in knee osteoarthritis (OA) (S rRan E fficacy in K nee O steoarthrI tis triA l (SEKOIA)). Material and methods: Patients with primary symptomatic knee OA were randomised to receive either SrRan 1 g/day or 2 g/day or placebo (SEKOIA study). A subset of these patients had MRIs at baseline, 12, 24 and 36 months to assess the knee cartilage volume and BMLs. Missing values were imputed and the analyses were adjusted according to Bonferroni. Results: In this MRI subset, the distribution of patients (modified intention-to-treat; n=330) was 113, 105 and 112 for SrRan 1 g/day, 2 g/day and placebo, respectively. The groups were fairly balanced at baseline regarding demographics, clinical symptoms or imaging characteristics. Treatment with SrRan 2 g/day significantly decreased CVL on the plateaus at 12 (p=0.002) and 36 (p=0.003) months compared with placebo. Of note, in the medial femur and plateau, SrRan 1 g/day, but not SrRan 2 g/day, had more CVL than placebo. In patients with BML in the medial compartment at baseline, the BML score at 36 months was decreased in both treatment groups compared with the placebo group (SrRan 1 g/day, p=0.002 and SrRan 2 g/day p=0.001, respectively), and CVL significantly decreased with SrRan 2 g/day (p=0.023) in the plateau compared with placebo. Conclusions: In knee OA patients, treatment with SrRan 2 g/day was found to have beneficial effects on structural changes by significantly reducing CVL in the plateau and BML progression in the medial compartment.